DMAC2L

Across TCGA pan-cancer cohorts, DMAC2L RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of DMAC2L’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where DMAC2L RNA is repressed in tumor relative to normal tissue. In most cancer types DMAC2L is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and LUAD are the cancer types where DMAC2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DMAC2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−1.009	<.001	11	view →
KIRC	Male	II,III,IV	−0.927	<.001	11	view →
LUAD	Female	II,III,IV	−0.813	<.001	9	view →
BLCA	Male	IV	−0.902	.004	8	view →
LUSC	Male	III,IV	−0.787	<.001	8	view →
LIHC	Male	All	+0.431	<.001	8	view →
COAD	Male	All	−0.444	<.001	7	view →
UCEC	All	All	−1.016	<.001	6	view →
KIRP	Male	All	−0.694	<.001	6	view →
BRCA	Female	All	−0.335	<.001	6	view →
CHOL	All	All	+0.964	<.001	5	view →
KICH	All	All	−0.678	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

DMAC2L–THCA

Open the THCA breakdown →